Revatio

sildenafil citrate

For suspension (oral) · NDA 203109

Last listed protection ended

January 31, 2026

The FDA listed 1 exclusivity for Revatio, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities